乳腺癌新辅助化疗与ER、PR、Her-2和Ki-67表达的关系分析

The relationship between neoadjuvant chemotherapy and the expression levels of ER,PR,Her-2 and Ki-67 in breast cancer

目的分析乳腺癌新辅助化疗疗效与生物学因子ER、PR、Her-2、Ki-67表达水平的关系。方法选择郑州大学第一附属医院2014年9月至2015年9月收治的76例乳腺癌患者,检测新辅助化疗前后ER、PR、Her-2、Ki-67的表达水平,分析其表达水平与新辅助化疗疗效的关系。结果化疗前ER阴性、PR阴性、Ki-67高表达患者总有效率高于ER阳性、PR阳性、Ki-67低表达患者(P<0.05)。新辅助化疗前后ER、PR、Her-2的表达阳性率差异无统计学意义(P>0.05);新辅助化疗后Ki-67表达阳性率下降,差异有统计学意义(P<0.05)。结论 ER阴性、PR阴性、Ki-67高表达的乳腺癌患者接受新辅助化疗可获得较高的临床疗效。新辅助化疗前后生物学因子ER、PR、Her-2的表达无变化,Ki-67的表达发生了变化。

Objective To investigate the relationship between neoadjuvant chemotherapy and the expression levels of ER,PR,Her-2 and Ki-67 in breast cancer. Methods Seventy-six patients with breast cancer treated in the First Affiliated Hospital of Zhengzhou University from September of 2014 to September of 2015 were selected. The expression levels of ER,PR,Her-2and Ki-67 before and after neoadjuvant chemotherapy were detected. The relationship between neoadjuvant chemotherapy and the expression levels of ER,PR,Her-2 and Ki-67 was analyzed. Results The total effective rates of patients with ER(-),PR(-),Ki-67( +) were higher than patients with ER( +),PR( +),Ki-67(-)( P < 0. 05). There was no difference in the positive rates of ER,PR,Her-2 before and after neoadjuvant chemotherapy( P > 0. 05). The positive rate of Ki-67 after neoadjuvant chemotherapy was lower than that before neoadjuvant chemotherapy,and the difference was statistically significant( P < 0. 05). Conclusion Breast cancer patients with ER(-),PR(-),Ki-67( +) can obtain a higher clinical therapeutic effect of neoadjuvant chemotherapy. After neoadjuvant chemotherapy,there was no change in the expression levels of ER,PR,Her-2 except Ki-67.